MedElevator
Войти в исследования The Journal of the Association of Physicians of India · 2026
Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mehta Vimal, Agarwal Nikhil, Mehra Pratishtha, Mehta Navya, Yusuf Jamal, Dabla Pradeep Kumar, Sukhija Sana, Safal Safal, Gupta Mohit, Kumar Surendra, Kathuria Sanjeev, Kumar Akhilesh, Duell P Barton, Pareek K K, Puri Raman
Аннотация
BACKGROUND: High-intensity statins are recommended in patients experiencing acute coronary syndrome (ACS) to lower low-density lipoprotein cholesterol (LDL-C) levels, but evidence-based recommended LDL-C goals often remain unmet. We assessed the therapeutic benefit of early LDL-C lowering and the safety of high-intensity atorvastatin and ezetimibe combination versus high-intensity atorvastatin alone in ACS.
METHODS: In this investigator-initiated trial, 254 patients admitted with ACS were randomized 1:1 to either atorvastatin 80 mg once daily (group A) or a combination of atorvastatin 80 mg and ezetimibe 10 mg once daily (group B). The first dose was administered orally immediately after diagnosis and then continued daily. The primary and secondary endpoints were percentage reductions in direct LDL-C measurements over the initial 4-week period and at 12 weeks, respectively.
RESULTS: The mean percentage reduction in LDL-C was 8.12% in group A vs 14.43% in group B (p < 0.001) at week 1, 16.62% in group A vs 28.34% in group B at 2 weeks (p < 0.001), 29.43% in group A vs 45.15% in group B at 4 weeks (p < 0.001), and 41.88% in group A vs 60.76% in group B (p < 0.001) at 12 weeks. Adverse events were similar in both groups.
CONCLUSION: Ezetimibe added to high-intensity statin therapy was well tolerated and resulted in an immediate and robust additional decrease in circulating LDL-C concentrations, with a markedly higher proportion of participants achieving LDL-C goals at 4 and 12 weeks. These promising results show that dual therapy started immediately at the diagnosis of ACS has the potential to improve cardiovascular outcomes in ACS.
METHODS: In this investigator-initiated trial, 254 patients admitted with ACS were randomized 1:1 to either atorvastatin 80 mg once daily (group A) or a combination of atorvastatin 80 mg and ezetimibe 10 mg once daily (group B). The first dose was administered orally immediately after diagnosis and then continued daily. The primary and secondary endpoints were percentage reductions in direct LDL-C measurements over the initial 4-week period and at 12 weeks, respectively.
RESULTS: The mean percentage reduction in LDL-C was 8.12% in group A vs 14.43% in group B (p < 0.001) at week 1, 16.62% in group A vs 28.34% in group B at 2 weeks (p < 0.001), 29.43% in group A vs 45.15% in group B at 4 weeks (p < 0.001), and 41.88% in group A vs 60.76% in group B (p < 0.001) at 12 weeks. Adverse events were similar in both groups.
CONCLUSION: Ezetimibe added to high-intensity statin therapy was well tolerated and resulted in an immediate and robust additional decrease in circulating LDL-C concentrations, with a markedly higher proportion of participants achieving LDL-C goals at 4 and 12 weeks. These promising results show that dual therapy started immediately at the diagnosis of ACS has the potential to improve cardiovascular outcomes in ACS.